✦ LIBER ✦

UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug

✍ Scribed by Kielhorn, Adrian; Porter, Duncan; Diamantopoulos, Alexander; Lewis, Gavin

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-Effectiveness Analysis of Biologica

✍ Ryazhenov, V.V.; Emchenko, I.V. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

Cost effectiveness of adding leflunomide

✍ Maetzel, Andreas ;Strand, Vibeke ;Tugwell, Peter ;Wells, George ;Bombardier, Cla 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 2 views

Indirect Comparison of Tocilizumab and O

✍ Gert J.D. Bergman; Marc C. Hochberg; Maarten Boers; Neil Wintfeld; Adrian Kielho 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 595 KB

Indirect comparisons of the efficacy of

✍ Salliot, C.; Finckh, A.; Katchamart, W.; Lu, Y.; Sun, Y.; Bombardier, C.; Keysto 📂 Article 📅 2010 🏛 BMJ Publishing Group 🌐 English ⚖ 299 KB

Efficacy of tocilizumab in patients with

✍ Yazici, Y.; Curtis, J. R.; Ince, A.; Baraf, H.; Malamet, R. L.; Teng, L. L.; Kav 📂 Article 📅 2011 🏛 BMJ Publishing Group 🌐 English ⚖ 301 KB

Phase III, multicenter, open-label, long

✍ Takeuchi, Tsutomu; Matsubara, Tsukasa; Urata, Yukitomo; Suematsu, Eiichi; Ohta, 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 250 KB